| 2024 – 2025 | Memodio-App@Care - die erste multimodale App für Menschen mit leichter kognitiver Störung und milder Demenz – eine Pilotstudie (memodio GmbH; DRKS00033494; Site-PI Reetz). |
| 2024 – 2025 | A multicenter, prospective, non-interventional study to determine the cutoff and clinical performance of the Elecsys® Amyloid Plasma panel and its component (Roche, RD006263; Site-PI Reetz) |
| 2020 – 2023 | Transthyretin-Associated Amyloidoses Outcome Survey (THAOS, NCT00628745, PI Brunkhorst) |
| 2021 – 2026 | A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer’s Disease (EVOKE, Sponsor Novo Nordisk NCT04777396, Site-PI Reetz) |
| 2021 – 2024 | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of AlZ-801 in Subjects with Early Alzheimer’s Disease and APOE4/4 Genotype, NCT04770220 APOLLOE4 Site-PI Schulz) |
| 2021 – 2025 | A Natural History Study to TRACK Brain and Spinal Cord Changes in Individuals With Friedreich Ataxia (TRACK-FA, NCT04349514, Site-PIs Reetz, Dogan, Romanzetti, Schulz) |
| 2021 – 2024 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients With Early Stage of Huntington Disease (Proof-HD, Sponsor Prilenia Neurotherapeutics, NCT04556656, Site-PI Reetz) |
| 2021 – 2023 | Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (EMBARK, Sponsor Biogen, NCT04241068, Site-PI Schulz, Deputy Reetz) |
| 2020 – 2021 | The prevalence and distribution of CYP2C9 polymorphisms of MS patients in a multi-center epidemiological study (Variety, NCT CBAF312ADE02, Site PI Tauber) |
| 2019 – 2021 | A randomized, multicenter, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of intrathecally administered RO7234292 in patients with Huntington’s disease (NCT03842969, Site-PI Reetz) |
| 2019 – 2020 | A double-blind, placebo-controlled study on the effects of MIN-102 on biochemical, imaging, neurophysiological, and clinical markers in patients with Friedreich’s ataxia (phase 2, FRAMES, NCT03917225, Site-PI Reetz) |
| 2019 – 2020 | A multimodal imaging study on physical activity in patients with Alzheimer’s disease (Dementia-MOVE, IIT, NCT03939286, PIs Häger, Reetz) |
| 2019 – 2021 | Prevention Stroke/Carotid Artery Stenosis Phase II (PRECISE, NCT02677545, Site-PI Reich) |
| 2018 – 2023 | Strukturierte ambulante Nachsorge nach Schlaganfall (SANO, Site-PI Schulz) |
| 2018 – 2021 | A multicenter, randomized, double-blind, placebo-controlled study of the safety, pharmacokinetics, and pharmacodynamics of BIIB054 in subjects with Parkinson’s disease (SPARK, NCT03318523, Site-PI Reetz) |
| 2018 – 2021 | Prevention of epilepsy in stroke patients at high risk of developing unprovoked seizures: anti-epileptogenic effects of eslicarbazepine acetate (BIA, Phase IIa, EudraCT 2018-002747-29, Site-PI Schulz) |
| 2018 – 2020 | Physical Activity and Exercise outcomes in Huntington’s disease (PACE-HD): A longitudinal cohort study with nested randomized pragmatic controlled trial to evaluate physical activity and exercise related outcomes in people with Huntington’s disease. (NCT03344601, Site-PI Reetz) |
| 2016 – 2019 | A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Aducanumab (BIIB037) in subjects with early Alzheimer’s disease (NCT02477800, Site-PI Schulz, Deputy Reetz) |
| 2015 – 2021 | Registry Study/Acute Stroke with NOAK, VKA (NCT02533960, Site-PI Schiefer) |
| 2015 – 2018 | A parallel-group, double-blind, long-term safety and efficacy trial of Verubecestat (MK-8931, SCH 900931) in subjects with amnestic mild cognitive impairment due to Alzheimer’s disease (Prodromal AD), (NCT0153601, Site-PI Reetz) |
| 2015 – 2017 | An open label extension study to investigate the long-term safety, tolerability and efficacy of PF-02545920 in subjects with Huntington’s disease who previously completed study A8241021 (NCT02342548, Site-PI Reetz) |
| 2015 – 2016 | A phase 2, randomized, placebo controlled, double blind proof-of-concept study of the efficacy and safety of PF-02545920 in subjects with Huntington’s disease (NCT02197139, Site-PI Reetz) |
| 2014 – 2016 | A dose escalation, proof of concept, phase IIa study to investigate the safety and tolerability, the pharmacokinetic and the pharmacodynamic of BN82451B, administered twice daily over 4 weeks, in male patients with Huntington’s disease (NCT02231580, Site PI Schiefer, Deputy Reetz) |
| 2013 – 2016 | A randomized, parallel-group interventional trial with real-time functional Magnetic Resonance Imaging Neurofeedback in elderly and subjects with prodromal Alzheimer’s disease (NCT03070821, IIT, PI Reetz) |
| 2013 – 2015 | A randomized, placebo controlled, parallel-group, double-blind efficacy and safety trial of MK-8931 with a long-term double-blind extension in subjects with mild to moderate Alzheimer’s disease (NCT01496170, Site-PI Schulz, Deputy Reetz) |
| 2010 – 2013 | Modulation of beta-amyloid levels in CSF and plasma by GSK933776 in patients with mild Alzheimer’s disease or mild cognitive impairment (NCT01424436, Site-PI Schulz, Deputy Reetz) |
| 2010 – 2013 | A phase 3, double-blind double-dummy, placebo- and active-controlled dose-range-finding efficacy and safety study of Preladenant in subjects with early Parkinson’s disease, Site-PI Schulz) |
| 2009 – 2009 | A double-blind placebo-controlled study of the safety, tolerability and efficacy of 12 months’ treatment with ACI-91 in patients with mild to moderate Alzheimer’s disease (EudraCT number 2008-005260-14, Site-PI Schulz) |
